Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial

Objectives To address whether nondihydropyridine calcium-channel blocker added-on angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular outcomes in type 2 diabetes patients. Design The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment. Main outcome was persistent macroalbuminuria (albuminuria >200 μg/min in two consecutive visits). Treatment targets were SBP/DBP less than 120/80 mmHg and HbA1C less than 7%. Results Over a median follow-up of 4.5 years, 18 patients (13%) on VeraTran vs. 15 (10.5%) on trandolapril [unadjusted hazard ratio (95% confidence interval [CI]) 1.07 (0.54–2.12), P = 0.852] progressed to macroalbuminuria, respectively; 62 (44.9%) vs. 71 (49.7%) [0.80 (0.57–1.12), P = 0.198] regressed to normoalbuminuria (urinary albumin excretion <20 μg/min), and 20 (14.5%) vs. 21 (14.7%) [hazard ratio 0.93 (0.50–1.72), P = 0.816] had major cardiovascular events. BP and metabolic control were similar between groups. Patients with cardiovascular events were significantly less [13 (9.8%) vs. 28 (18.9%), hazard ratio: 0.37 (0.19–0.71), P = 0.003] among those regressing to normoalbuminuria than those without regression. Difference was independent of treatment allocation and was significant also after adjusting for baseline characteristics [0.40 (0.20–0.79), P = 0.009], follow-up SBP [0.40 (0.20–0.80), P = 0.010] or DBP [0.36 (0.18–0.73), P = 0.004] BP or HbA1C [0.43 (0.21–0.88), P = 0.021]. Conclusion In hypertensive type 2 diabetes patients with microalbuminuria, verapamil added-on trandolapril did not improve renal or cardiovascular outcomes. Independent of verapamil, trandolapril normalized albuminuria in half of patients and this translated into significant cardioprotection.

[1]  T. Uzu,et al.  Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes , 2007, Diabetes.

[2]  G. Remuzzi,et al.  Time to abandon microalbuminuria? , 2006, Kidney international.

[3]  E. Montanya,et al.  Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. , 2005, Diabetes research and clinical practice.

[4]  K. Narayan,et al.  Trends in cardiovascular complications of diabetes. , 2005, JAMA.

[5]  M. Mauer,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[6]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[7]  G. Bakris,et al.  Differential effects of calcium antagonist subclasses on markers of nephropathy progression. , 2004, Kidney international.

[8]  A. Perna.  The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. , 2003, Controlled clinical trials.

[9]  G. Viberti,et al.  Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.

[10]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[11]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[12]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[13]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[14]  G. Bakris,et al.  Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. , 1998, Kidney international.

[15]  G. Remuzzi,et al.  The diagnosis of renal involvement in non‐insulin-dependent diabetes mellitus , 1997, Current opinion in nephrology and hypertension.

[16]  S. Leurgans,et al.  Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.

[17]  H. Parving,et al.  Prevention of diabetic renal disease with special reference to microalbuminuria , 1995, The Lancet.

[18]  W. D. Ray.  4. Modelling Survival Data in Medical Research , 1995 .

[19]  M. Lishner,et al.  Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.

[20]  H. Keen,et al.  MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUS , 1982, The Lancet.

[21]  M. Abbal,et al.  FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE , 1975, The Lancet.